0.4167
Azitra Inc stock is traded at $0.4167, with a volume of 3.80M.
It is up +4.70% in the last 24 hours and down -1.07% over the past month.
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.
See More
Previous Close:
$0.398
Open:
$0.3582
24h Volume:
3.80M
Relative Volume:
0.63
Market Cap:
$6.24M
Revenue:
$1.27M
Net Income/Loss:
$-11.28M
P/E Ratio:
-0.0186
EPS:
-22.4496
Net Cash Flow:
$-10.46M
1W Performance:
+21.91%
1M Performance:
-1.07%
6M Performance:
-39.60%
1Y Performance:
+83.57%
Azitra Inc Stock (AZTR) Company Profile
Name
Azitra Inc
Sector
Industry
Phone
203 646 6446
Address
21 Business Park Drive, Branford
Compare AZTR with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
AZTR
Azitra Inc
|
0.4167 | 6.24M | 1.27M | -11.28M | -10.46M | -22.45 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
459.00 | 117.92B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
673.60 | 73.64B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
639.41 | 38.85B | 1.86B | -40.29M | -1.28B | -0.85 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
256.45 | 33.20B | 2.09B | -332.26M | 16.06M | -2.62 |
![]()
BNTX
Biontech Se Adr
|
119.83 | 28.73B | 3.30B | -501.07M | 1.03B | -2.1146 |
Azitra Inc Stock (AZTR) Latest News
Volcon, Inc. and GlucoTrack, Inc. See Massive Gains, While Omega Therapeutics and Universe Pharmaceuticals Struggle – market - HPBL
Monitoring Azitra Inc (AZTR) after recent insider movements - Knox Daily
AZTR’s price-to-free cash flow ratio: How it affects investment decisions - US Post News
Azitra Inc (AZTR) looking to reclaim success with recent performance - SETE News
Azitra Inc. Enters into Placement Agency Agreement with Maxim Group LLC - Defense World
Azitra (NYSEAMERICAN: AZTR) Closes Offering and Enters Into Agreement with Investors - Defense World
Certain Warrants of Azitra, Inc. are subject to a Lock-Up Agreement Ending on 8-FEB-2025. - Marketscreener.com
Azitra Inc. issues new warrants in connection with stock sale By Investing.com - Investing.com Nigeria
Azitra Inc. issues new warrants in connection with stock sale - MSN
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Azitra secures $930K in registered direct offering By Investing.com - Investing.com Australia
Azitra Prices of $930.0 Thousand Registered Direct Offering of Common Stock - citybiz
Azitra secures $930K in registered direct offering - Investing.com India
Azitra Prices $930,000 Registered Direct Offering -February 04, 2025 at 02:49 pm EST - Marketscreener.com
Struggling Biotech Azitra Raises Emergency Capital: Inside the $930K Deal - StockTitan
AZTR’s price-to-free cash flow ratio: What it means for investors - US Post News
Azitra Inc (AZTR) Stock: A Year of Decreases and Increases - The InvestChronicle
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Why Palantir Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket - Benzinga
Azitra, Inc. to Present at the BIO CEO & Investor Conference - The Malaysian Reserve
Azitra Inc Stock (AZTR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cap:
|
Volume (24h):